The Use of Empagliflozin Post Myocardial Infarction

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is mainly used for the treatment of type 2 diabetes mellitus. The study's objective was to assess empagliflozin's effects and impacts on post-myocardial patients to highlight its worth in comparison to alternative the...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-06, Vol.15 (6), p.e40602
Main Authors: Ravendran, Kapilraj, Madouros, Nikolaos, Yoztyurk, Edzhem, Wilson, Aishwarya, Jeejo, Maria J, Camelio, Monica E, Sinha, Akatya, George, Ananya, Rai, Mriganka, Malik, Hussain K
Format: Article
Language:English
Subjects:
Antidiabetics
Blood pressure
Cardiology
Cardiomyocytes
Cardiovascular disease
Diabetes
Ejection fraction
Endocrinology/Diabetes/Metabolism
Family/General Practice
Glucose
Heart attacks
Heart failure
Heart rate
Hospitalization
Ischemia
Mortality
Peptides
Source studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is mainly used for the treatment of type 2 diabetes mellitus. The study's objective was to assess empagliflozin's effects and impacts on post-myocardial patients to highlight its worth in comparison to alternative therapies. Only studies evaluating the effects of empagliflozin on individuals who have undergone a myocardial infarction (MI) are included in this review of the literature, which employed PubMed, Google Scholar, and Embase. To compare the advantages of empagliflozin for individuals who have recently experienced a myocardial infarction, abstracts from pertinent articles were retrieved, and complete publications were reviewed. A total of four articles were reviewed, which showed that in patients who suffered from a recent MI, empagliflozin caused a significant decrease in N-terminal pro-brain natriuretic peptide (NT-proBNP). Additionally, it was shown that these individuals had better echocardiographic results for both structural and functional metrics. With studies showing a significantly larger median NT-proBNP decrease with empagliflozin compared to placebo among patients hospitalised with an acute big MI when empagliflozin was started early and administered in addition to the post-MI care suggested by guidelines, it is safe to say that the benefits outweigh the risks. There are currently larger double-blind trials in progress to prove the hypothesis of the benefits of empagliflozin for post-MI patients.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.40602